TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Core Viewpoint - TScan Therapeutics, Inc. is participating in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, focusing on its T cell receptor-engineered T cell therapies for cancer treatment [1]. Company Overview - TScan Therapeutics is a clinical-stage biotechnology company dedicated to developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed for patients with hematologic malignancies, specifically to prevent relapse after allogeneic hematopoietic cell transplantation, as part of the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse antigens and are compatible with multiple HLA types, to create customized multiplex TCR-T therapies for various cancers, including the PLEXI-T Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Event Information - A webcast of the fireside chat will be accessible on the "Events and Presentations" section of TScan's website, with an archived replay available for 90 days post-event [2].